{
  "pmcid": "11536912",
  "sha256": "de9215a68bdbfa5266e7ce91ca4484cecba994a5771fcb8e1eee97ef67eb9923",
  "timestamp_utc": "2025-11-09T22:04:49.204095+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.717950310559011,
    "reading_ease": 16.21920289855072,
    "word_count": 230
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial on Nurses' Roles in Smoking Cessation Interventions"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomly assigned to intervention or control groups"
      },
      "Participants": {
        "score": 2,
        "evidence": "The study included patients with chronic obstructive pulmonary disease (COPD) across various healthcare settings."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Nurses employed motivational interviewing and the 5A method, distributing pamphlets and providing face-to-face education. The comparator involved standard care without nurse-led interventions."
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was smoking cessation rates, measured over a six-month period."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Participants were randomly assigned to intervention or control groups, with allocation concealment ensured."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Outcome assessors were blinded to group assignments."
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Smoking cessation rates improved significantly in the intervention group (mean difference = 5.2%, 95% CI 3.1 to 7.3; p = 0.01)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "OSF platform (https://osf.io/ba72e/)."
      },
      "Funding": {
        "score": 0,
        "evidence": "Not specified."
      }
    },
    "total_score": 16,
    "max_score": 25
  }
}